Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. ASEP Medical Holdings's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was C$0.28 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was C$1.51 Mil.
ASEP Medical Holdings (XCNQ:ASEP) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
ASEP Medical Holdings Selling, General, & Admin. Expense Related Terms
ASEP Medical Holdings Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for ASEP Medical Holdings's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASEP Medical Holdings Selling, General, & Admin. Expense Chart
XCNQ:ASEP vs VRTX, REGN, MRNA: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, ASEP Medical Holdings's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ASEP Medical Holdings Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ASEP Medical Holdings's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where ASEP Medical Holdings's Selling, General, & Admin. Expense falls into.
ASEP Medical Holdings Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of C$1.51 Mil mean?
ASEP Medical Holdings (XCNQ:ASEP) has a Selling, General, & Admin. Expense of C$1.51 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ASEP Medical Holdings and its competitors.
Is ASEP Medical Holdings' Selling, General, & Admin. Expense too high?
ASEP Medical Holdings' current Selling, General, & Admin. Expense is C$1.51 Mil. Overall, ASEP Medical Holdings has a GF Score™ of 16/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ASEP Medical Holdings' Selling, General, & Admin. Expense compare to VRTX and REGN?
ASEP Medical Holdings' Selling, General, & Admin. Expense of C$1.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ASEP Medical Holdings and its competitors. ASEP Medical Holdings's current Selling, General, & Admin. Expense is C$1.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASEP Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ASEP Medical Holdings (XCNQ:ASEP) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.40, compared to a current price of C$0.15 — trading 62.5% below its estimated fair value. The current Selling, General, & Admin. Expense is C$1.51 Mil. ASEP Medical Holdings' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For ASEP Medical Holdings (XCNQ:ASEP), the current Selling, General, & Admin. Expense is C$1.51 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ASEP Medical Holdings (XCNQ:ASEP) Overvalued in 2026?
Based on GuruFocus' analysis, ASEP Medical Holdings stock appears to be undervalued.
The current stock price of C$0.15 is trading 62.5% below its estimated GF Value™ of C$0.40.
GuruFocus considers ASEP Medical Holdings to be Possible Value Trap.
Key valuation signals for XCNQ:ASEP:
Selling, General, & Admin. Expense: C$1.51 Mil
GF Value™: C$0.40 vs. price of C$0.15 (62.5% below fair value)
No single metric tells the full story. See the XCNQ:ASEP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ASEP Medical Holdings Inc is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. Diagnostic and therapeutic solutions represent tremendous clinical and commercial potential, through rapid diagnostics and uniquely effective treatments. Its Diagnostic has developed a novel diagnostic assay for the early and rapid risk assessment of sepsis. Therapeutic offering: Patented peptide technology targets infection-causing biofilms and reduces inflammation.
16GF Score
Get the complete analysis for XCNQ:ASEP
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:ASEP has been successfully added to your 
